| carbidopa/levodopa / Generic mfg. |
NCT02763839: Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg) |
|
|
| Completed | 1 | 19 | Europe | BIA 3-202, Placebo, Sinemet 25/100 | Bial - Portela C S.A. | Parkinson's Disease | 07/01 | 07/01 | | |
NCT02774564: Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa |
|
|
| Completed | 1 | 16 | Europe | BIA 3-202, Nebicapone, Placebo, Sinemet® | Bial - Portela C S.A. | Parkinson's Disease | 11/05 | 11/05 | | |
NCT00845000: Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) |
|
|
| Completed | 1 | 12 | NA | SCH 420814 10 mg, SCH 420814 100 mg, Placebo, Levodopa, Carbidopa | Merck Sharp & Dohme LLC, Oregon Health and Science University | Parkinson Disease | 04/10 | 05/10 | | |
|
|
NCT01484990: A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease |
|
|
| Completed | 1 | 19 | NA | Levodopa-Carbidopa | AbbVie, Quintiles, Inc. | Parkinson Disease | 09/10 | 09/10 | | |
| Completed | 1 | 20 | Europe | levodopa, carbidopa, ODM-104, Sinemet | Orion Corporation, Orion Pharma | Parkinson's Disease | 02/15 | 02/15 | | |
NCT02486432: A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) |
|
|
| Completed | 1 | 6 | Europe | Levodopa/Carbidopa (Sinemet), Sinemet | NeuroDerm Ltd., Quotient Clinical | Parkinson's Disease | 04/15 | 04/15 | | |
NCT02812394: A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets |
|
|
| Completed | 1 | 24 | US | CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®, carbidopa/levodopa | Acorda Therapeutics | Parkinson Disease | 08/16 | 09/16 | | |
NCT03140956: Pharmacokinetic of Levodopa Study in Healthy Males |
|
|
| Completed | 1 | 20 | Europe | Levodopa, carbidopa, ODM-104, Sinemet | Orion Corporation, Orion Pharma | Parkinson Disease | 07/17 | 08/17 | | |
NCT03665454: PF 06412562 in Subjects With Advanced Stage Parkinson's Disease |
|
|
| Completed | 1 | 8 | US | PF-06412562, Standard of Care Placebo, Sinemet | Milton S. Hershey Medical Center, Pfizer | Parkinson Disease | 03/19 | 04/19 | | |
| Completed | 1 | 31 | US | Levodopa, Carbidopa | Kevin J. Black, MD, The Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease | 10/19 | 10/19 | | |
NCT03929068: Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis |
|
|
| Completed | 1 | 15 | US | carbidopa-levodopa, Sinemet, Placebo Oral Tablet | Washington University School of Medicine | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 07/22 | 07/22 | | |
STIMO-PHARMA, NCT04052776: Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES |
|
|
| Completed | 1 | 3 | Europe | Buspirone, Levodopa-Carbidopa, Buspirone + Levodopa-Carbidopa, Placebo oral tablet | Centre Hospitalier Universitaire Vaudois, Ecole Polytechnique Fédérale de Lausanne | Spinal Cord Injuries, Drug Effect | 10/23 | 10/23 | | |
NCT05471609: Sustained Release Oral Formulation for Treatment of Parkinson's Disease |
|
|
| Suspended | 1 | 6 | US | levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B, levodopa/carbidopa oral formulation C | University of Minnesota | Idiopathic Parkinson Disease | 01/26 | 01/26 | | |
